NeuroDerm

Executive Summary

NeuroDerm is a privately held Israeli biopharmaceutical company focused on developing drug-device combination therapies for central nervous system disorders, particularly Parkinson's disease. Its lead candidate, ND0612, is a subcutaneous infusion system delivering a continuous liquid levodopa/carbidopa formulation aimed at reducing motor fluctuations in advanced Parkinson's patients. The device integrates digital health monitoring to optimize dosing. With over two decades of R&D and $150M raised, NeuroDerm has advanced ND0612 through Phase 3 trials, demonstrating statistically significant reductions in OFF time and increased ON time without troublesome dyskinesia. The company is now preparing for regulatory submissions, potentially transforming the standard of care for Parkinson's motor complications. NeuroDerm's pipeline also includes earlier-stage programs for other CNS indications, but ND0612 remains the primary value driver. Given the positive Phase 3 data and clear unmet need in Parkinson's, the company is well-positioned for a successful commercialization path, whether through strategic partnerships or independent launch.

Upcoming Catalysts (preview)

• Q3 2026NDA Submission for ND0612 to FDA85% success
• Q4 2026Announcement of Partnership or Licensing Deal for Commercialization70% success
• Q2 2026Pivotal Phase 3 Data Publication in Peer-Reviewed Journal90% success